13 June 2022
: Case report
[In Press] A Case of a Rare Parathyroid Hormone (PTH)-Producing Neuroendocrine Tumor
Challenging differential diagnosis, Rare disease
Catherine Dianne Quinn1ABCDEFG, Fihr Chaudhary2ABEF, Aron Gould-Simon3BD, Baorong Chen4BD, Harsimran Singh Bhandal5BEF, Uzair Chaudhary1ABDEGDOI: 10.12659/AJCR.935783
Am J Case Rep In Press; DOI: 10.12659/AJCR.935783
Available online: 2022-06-13, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Neuroendocrine neoplasms are commonly seen in association with hormone production, and clinical signs that arise from these hormonal effects often manifest as the first presentation of malignancy. The excess production of parathyroid hormone (PTH) in particular, however, is primarily sporadic (80-85%) in clinical settings. In the context of malignancy, hyperparathyroidism manifestations arise most frequently from non-neuroendocrine pulmonary tumors through a ligand mimicker, parathyroid hormone-related peptide (PHrP). Excess PTH or PTHrP production has been very rarely described in association with gastrointestinal tumors and almost never described as a primary paraneoplastic syndrome from a neuroendocrine tumor (NET) alone.
CASE REPORT
We present a patient with a prior surgically resected carcinoid tumor who later presented with an elevated parathyroid hormone level, hypercalcemia, and clinical manifestations of primary hyperparathyroidism. She was found to have a low-grade, recurrent neuroendocrine tumor on resection of a parathyroid mass suspected to be a productive adenoma. Despite no longer having parathyroid glands given the extent of resection, her PTH level remained elevated and was rising. Further investigation via repeat sestamibi nuclear scan excluded the possibility of exogenous parathyroid tissue, and subsequent dotatate positron emission tomography/computed tomography (PET/CT) revealed the source of the PTH production: multiple sites of metastatic neuroendocrine tumors producing native PTH.
CONCLUSIONS
This case highlights the rare possibility of NETs to secrete PTH and the importance of considering early staging with dotatate PET/CT to evaluate the extent of disease. Additionally, our case reveals the importance of considering NET as an alternative etiology for refractory hypercalcemia.
Keywords: Neuroendocrine Tumors; Paraneoplastic Endocrine Syndromes; Parathyroid Hormone; Positron Emission Tomography Computed Tomography; Octreotide; Gallium Ga 68 Dotatate; Parathyroid Hormone-Related Protein (1-108)
SARS-CoV-2/COVID-19
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936128
03 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936832
In Press
24 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936288
24 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936641
24 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936513
22 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936862
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744